Condition
Schizophrenic Psychoses
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Completed2
Unknown2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06807242CompletedPrimary
Implementation of a Tool for Reduction of Cardiovascular Risk in Patients with Severe Mental Disorders ( HEALTHYHEART )
NCT05324865Not ApplicableUnknownPrimary
The Effect of Progressive Muscle Relaxation on Psychological Symptoms and Mental Well-Being in Patients With Schizophrenia
NCT02388607UnknownPrimary
Sustained Attention Abilities in Schizophrenia
NCT01354132Phase 2CompletedPrimary
N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
Showing all 4 trials